Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead... see more

Recent & Breaking News (GREY:ATHXQ)

Athersys, Inc. Announces $12 Million Registered Direct Offering

Business Wire August 15, 2022

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 11, 2022

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

Business Wire August 8, 2022

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer

Business Wire August 4, 2022

Athersys to Host Second Quarter Financial Results Call

Business Wire July 26, 2022

Athersys and Aspire Capital Fund Terminate Relationship

Business Wire July 8, 2022

Thinking about buying stock in Cowen, OneConnect Financial Tech, Faraday Future Intelligent Electric, RA Medical Systems, or Athersys?

PR Newswire July 5, 2022

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

Business Wire June 21, 2022

Athersys Postpones Annual Meeting of Stockholders

Business Wire June 9, 2022

Athersys Hosting KOL Panel Event to Discuss TREASURE Data

Business Wire June 8, 2022

Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs

Business Wire June 2, 2022

Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study

Business Wire May 20, 2022

Athersys to Participate in the H.C. Wainwright Global Investment Conference

Business Wire May 13, 2022

Athersys Reports First Quarter 2022 Results

Business Wire May 6, 2022

Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference

Business Wire May 2, 2022

Athersys to Announce First Quarter Financial Results on May 6

Business Wire April 29, 2022

 Athersys Reports That Its Partner, HEALIOS K.K., Provides Updates on MultiStem® Clinical Programs in Japan

Business Wire April 4, 2022

Athersys to Participate in Two Upcoming Investor Conferences

Business Wire April 1, 2022

Athersys Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

Business Wire March 15, 2022

Athersys Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 17, 2022